论文部分内容阅读
目的:观察加味逍遥丸联合缬沙坦治疗围绝经期高血压病患者的临床疗效,并初步探讨其作用机制。方法:将79例患者随机分为2组,对照组40例单用缬沙坦治疗,治疗组39例用加味逍遥丸联合缬沙坦治疗。结果:临床降压总有效率治疗组为82.1%,对照组为70.0%,2组比较,差异无显著性意义(P>0.05)。治疗组治疗后有效地降低收缩压(P<0.05);对照组治疗后收缩压虽有降低,但差异无显著性意义(P>0.05)。治疗后治疗组能有效地降低血浆同型半胱氨酸(HCY)水平(P<0.01),并能升高血浆高密度脂蛋白胆固醇(HDL-C)水平(P<0.05);治疗后对照组HCY、HDL-C有改善趋势,但差异无显著性意义(P>0.05)。治疗后2组均不能改善颈动脉内膜中层厚度(CIMT)阳性数目。结论:加味逍遥丸联合缬沙坦治疗能显著降低血压和改善部分动脉硬化相关的心脑血管疾病风险预测指标。
Objective: To observe the clinical effects of Jiawei Xiaoyao Pills combined with valsartan in the treatment of perimenopausal patients with essential hypertension and to explore its mechanism. Methods: 79 patients were randomly divided into two groups, the control group of 40 patients treated with valsartan alone, the treatment group of 39 patients with Modified Xiaoyao Pills combined with valsartan. Results: The total effective rate of clinical treatment was 82.1% in the treatment group and 70.0% in the control group. There was no significant difference between the two groups (P> 0.05). The treatment group effectively reduced the systolic blood pressure (P <0.05). The systolic blood pressure of the control group decreased after treatment, but the difference was not significant (P> 0.05). After treatment, the treatment group can effectively reduce the level of plasma homocysteine (HCY) (P <0.01), and increase the level of plasma HDL-C (P <0.05). After treatment, the control group HCY, HDL-C have improved trend, but the difference was not significant (P> 0.05). Both groups did not improve the number of carotid intima-media thickness (CIMT) positive after treatment. Conclusion: Jiawei Xiaoyao Pills combined with valsartan can significantly reduce the blood pressure and improve the risk of cardiovascular diseases related to some atherosclerosis predictors.